NO20052991L - Kinazolinforbindelser. - Google Patents

Kinazolinforbindelser.

Info

Publication number
NO20052991L
NO20052991L NO20052991A NO20052991A NO20052991L NO 20052991 L NO20052991 L NO 20052991L NO 20052991 A NO20052991 A NO 20052991A NO 20052991 A NO20052991 A NO 20052991A NO 20052991 L NO20052991 L NO 20052991L
Authority
NO
Norway
Prior art keywords
quinazoline
therapy
formula
preparation
methods
Prior art date
Application number
NO20052991A
Other languages
English (en)
Norwegian (no)
Other versions
NO20052991D0 (no
Inventor
Andrew Austen Mortlock
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of NO20052991D0 publication Critical patent/NO20052991D0/no
Publication of NO20052991L publication Critical patent/NO20052991L/no

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65583Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65586Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system at least one of the hetero rings does not contain nitrogen as ring hetero atom

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
NO20052991A 2002-12-24 2005-06-17 Kinazolinforbindelser. NO20052991L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP02293239 2002-12-24
PCT/GB2003/005636 WO2004058752A1 (fr) 2002-12-24 2003-12-22 Composes de quinazoline

Publications (2)

Publication Number Publication Date
NO20052991D0 NO20052991D0 (no) 2005-06-17
NO20052991L true NO20052991L (no) 2005-07-19

Family

ID=32668916

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20052991A NO20052991L (no) 2002-12-24 2005-06-17 Kinazolinforbindelser.

Country Status (12)

Country Link
US (1) US7407946B2 (fr)
EP (1) EP1575946A1 (fr)
JP (1) JP2006516138A (fr)
KR (1) KR20050087863A (fr)
CN (1) CN1753889A (fr)
AU (1) AU2003290322A1 (fr)
BR (1) BR0317680A (fr)
CA (1) CA2508921A1 (fr)
MX (1) MXPA05006920A (fr)
NO (1) NO20052991L (fr)
WO (1) WO2004058752A1 (fr)
ZA (1) ZA200504828B (fr)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI1847539T1 (sl) * 2002-12-24 2010-01-29 Astrazeneca Ab Kinazolinski derivati
CL2004000797A1 (es) * 2003-04-16 2005-05-27 Astrazeneca Ab Compuestos derivados de quinazolina, inhibidores de aurora quinasa; procedimiento de preparacion; composicion farmaceutica; y su uso para preparar un medicamento para tratar cancer colorrectal, de mama, de pulmon, de prostata, de vejiga, renal o panc
JP2006526599A (ja) * 2003-06-02 2006-11-24 アストラゼネカ アクチボラグ 癌のような増殖性疾患の治療のためのオーロラキナーゼインヒビターとしての(3−((キナゾリン−4−イル)アミノ)−1h−ピラゾール−1−イル)アセトアミド誘導体及び関連化合物
US8153643B2 (en) 2004-10-12 2012-04-10 Astrazeneca Ab Quinazoline derivatives
EP1812439B2 (fr) 2004-10-15 2017-12-06 Takeda Pharmaceutical Company Limited Inhibiteurs de kinase
US8119655B2 (en) 2005-10-07 2012-02-21 Takeda Pharmaceutical Company Limited Kinase inhibitors
EP1785420A1 (fr) * 2005-11-14 2007-05-16 4Sc Ag Analogues de thiazole et leurs utilisation
WO2007099323A2 (fr) * 2006-03-02 2007-09-07 Astrazeneca Ab Dérivés de la quinoline
UY30183A1 (es) 2006-03-02 2007-10-31 Astrazeneca Ab Derivados de quinolina
US20090042910A1 (en) * 2006-03-02 2009-02-12 Frederic Henri Jung Quinoline derivatives for treating cancer
WO2007113548A1 (fr) * 2006-04-06 2007-10-11 Astrazeneca Ab Dérivés de naphtyridine
US20070258976A1 (en) * 2006-05-04 2007-11-08 Ward Keith W Combination Therapy for Diseases Involving Angiogenesis
GB0609617D0 (en) 2006-05-16 2006-06-21 Astrazeneca Ab Process & intermediate
EA200970361A1 (ru) 2006-10-09 2010-02-26 Такеда Фармасьютикал Компани Лимитед Ингибиторы киназы
EP2149565A1 (fr) 2008-07-24 2010-02-03 Bayer Schering Pharma AG Dérivés de chinazoline substitués par du sulfonamide en tant que modulateurs d'immunité pour le traitement de inflammations et allergies
ES2559209T3 (es) 2010-04-14 2016-02-11 Bristol-Myers Squibb Company Nuevos activadores de la glucocinasa y métodos de uso de los mismos
CA3142576A1 (fr) * 2011-01-21 2012-07-26 Basilea Pharmaceutica Ag Utilisation du bubr1 comme biomarqueur de reponse medicamenteuse aux furazanobenzimidazoles
EP2956138B1 (fr) 2013-02-15 2022-06-22 Kala Pharmaceuticals, Inc. Composés thérapeutiques et utilisations de ceux-ci
US9688688B2 (en) 2013-02-20 2017-06-27 Kala Pharmaceuticals, Inc. Crystalline forms of 4-((4-((4-fluoro-2-methyl-1H-indol-5-yl)oxy)-6-methoxyquinazolin-7-yl)oxy)-1-(2-oxa-7-azaspiro[3.5]nonan-7-yl)butan-1-one and uses thereof
ES2831625T3 (es) 2013-02-20 2021-06-09 Kala Pharmaceuticals Inc Compuestos terapéuticos y sus usos
US9890173B2 (en) 2013-11-01 2018-02-13 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
MX355330B (es) 2013-11-01 2018-04-16 Kala Pharmaceuticals Inc Formas cristalinas de compuestos terapeuticos y sus usos.
CA3036340A1 (fr) 2016-09-08 2018-03-15 Kala Pharmaceuticals, Inc. Formes cristallines de composes therapeutiques et leurs utilisations
KR20190051010A (ko) 2016-09-08 2019-05-14 칼라 파마슈티컬스, 인크. 치료 화합물의 결정형 및 그의 용도
AU2017324713B2 (en) 2016-09-08 2020-08-13 KALA BIO, Inc. Crystalline forms of therapeutic compounds and uses thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9922171D0 (en) 1999-09-21 1999-11-17 Zeneca Ltd Chemical compounds
CA2384291A1 (fr) 1999-09-21 2001-03-29 Astrazeneca Ab Derives de quinazoline et leur utilisation comme produits pharmaceutiques
NZ522696A (en) 2000-06-28 2004-08-27 Astrazeneca Ab Substituted quinazoline derivatives and their use as inhibitors
EP1408980A4 (fr) * 2001-06-21 2004-10-20 Ariad Pharma Inc Nouvelles quinazolines et leur utilisation
ATE412657T1 (de) * 2002-12-24 2008-11-15 Astrazeneca Ab Therapeutische quinazolin-derivate
SI1847539T1 (sl) * 2002-12-24 2010-01-29 Astrazeneca Ab Kinazolinski derivati

Also Published As

Publication number Publication date
KR20050087863A (ko) 2005-08-31
AU2003290322A1 (en) 2004-07-22
JP2006516138A (ja) 2006-06-22
MXPA05006920A (es) 2006-02-10
NO20052991D0 (no) 2005-06-17
US20060058523A1 (en) 2006-03-16
BR0317680A (pt) 2005-11-29
CN1753889A (zh) 2006-03-29
US7407946B2 (en) 2008-08-05
WO2004058752A1 (fr) 2004-07-15
ZA200504828B (en) 2008-02-27
CA2508921A1 (fr) 2004-07-15
EP1575946A1 (fr) 2005-09-21

Similar Documents

Publication Publication Date Title
NO20052991L (no) Kinazolinforbindelser.
NO20052855L (no) Fosfonoksykinazolinderivater og farmasoytisk anvendelse derav.
DE60324461D1 (de) Therapeutische quinazolin-derivate
NO20051695L (no) Nye spirokondenserte kinazolinoner og deres anvendelse som fosfodiestereaseinbibitorer
AU2910600A (en) Phenyl urea and phenyl thiourea derivatives
NO20053890L (no) Syntese av 4-amino-2-butenolklorider og anvendelse derav for fremstilling av 3-cyanokinoliner
NO20060972L (no) Pyridylderivater og deres anvendelse som terapeutiske midler
HUP0400246A2 (hu) 1,2,4-Trioxolánt tartalmazó maláriaellenes gyógyszerkészítmények és eljárás az előállításukra és az alkalmazásukra
NO20060665L (no) N-substituerte pyrazolyl-amidyl-benzimidazolyl C-kit inhibitorer
NO20085217L (no) Effektive pyrimidinderivater i behandlingen av kreft
NO20061157L (no) 4-pyramidonderivater og deres anvendelse som peptidylpeptidmeinbibitorer
NO20082101L (no) Pyrido-, pyrazo- og pyrimido-pyrimidinderivater som mTor inhibitorer
MXPA05013349A (es) Derivados de 2-amino-pirimidina como inhibidores de quinasa raf.
NO20060973L (no) Pyridylderivater og deres anvendelse som tempeutiske midler
NO20062474L (no) Antivirale midler bestaende av diazaindol-dikarbonyl-piperazinyl
DK0958296T3 (da) Heterocykliske forbindelser, fremgangsmåde til deres fremstilling og farmaceutiske præparater, der indeholder dem, og deres anvendelse i behandlingen af diabetes og beslægtede sygdomme
YU72804A (sh) N-aril-2-oksazolidinon-5-karboksamidi i njihovi derivati i njihova primena kao antibakterijskih sredstava
BRPI0413467A (pt) aminopironas e seu uso como inibidoras da atm
NO20060147L (no) Benzimidazolderivater, sammensetninger som inneholder slike, fremstilling derav og anvendelse derav
DK0751930T3 (da) Amidinoderivater anvendelige som nitrogenoxid-synthase-inhibitorer
NO20070570L (no) Forbindelser.
DE60121461D1 (de) Kondensierte pyridoindolderivate
NO20055749L (no) Sulfamat benzotiofenderivater som steroid sulfatase inhibitorer
DE69916066D1 (de) Neue benzoxazole mit pde-hemmender wirkung
GB0308201D0 (en) Novel compounds

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application